secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vicapsys Life Sciences, Inc. (VICP)
CIK:        0001468639
Form:       8-K
Filed at:   2022-09-28T23:59:59+00:00
Accession:  0001493152-22-027017
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vicapsys Life Sciences: Potts and Yurkowsky resign; Farrahar, Delaney, Rosenblum join board
--------------------------------------------------------------------------------

- Board accepted resignations of directors John Potts and Michael Yurkowsky effective September 22, 2022; no disagreement.
- Appointed Charles 'Charlie' Farrahar (CPA, former CFO of several biotechs) as director.
- Appointed Dr. Colleen Delaney, stem cell transplant physician and CSO of Deverra Therapeutics, as director.
- Appointed Richard Rosenblum, President/CFO of Payment Solutions Inc. and CEO of Harborview Capital Advisors, as director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468639/000149315222027017/0001493152-22-027017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468639/000149315222027017/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-027017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer